Navigation Links
Quest Diagnostics Reports Growth in Revenue and Earnings for Fourth Quarter 2008 and Provides 2009 Guidance
Date:1/26/2009

million reserve established for the previously disclosed NID matter, or approximately $700 million after such payment. Capital expenditures are expected to approximate $200 million.

Quest Diagnostics will hold its fourth quarter conference call on January 26, 2009 at 8:30 A.M. Eastern Time. A simulcast of the call is available by dialing 415-228-4961, passcode 3214469 and via the Internet at: www.questdiagnostics.com. Registered analysts may access the call at: www.streetevents.com. In addition, a replay of the call will be available from 10:30 A.M. on January 26 through midnight on February 23, 2009 to investors in the U.S. by dialing 866-431-7950. Investors outside the U.S. may dial 203-369-0981. No password is required for either number.

About Quest Diagnostics

Quest Diagnostics is the world's leading provider of diagnostic testing, information and services that patients and doctors need to make better healthcare decisions. The company offers the broadest access to diagnostic testing services through its network of laboratories and patient service centers, and provides interpretive consultation through its extensive medical and scientific staff. Quest Diagnostics is a pioneer in developing innovative diagnostic tests and advanced healthcare information technology solutions that help improve patient care.

Quest Diagnostics maintains one of the largest private clinical laboratory databases in the United States. The data is used to generate Quest Diagnostics Health Trends(TM), which identifies and tracks disease and wellness benchmarks, and the Drug Testing Index(R), which is published as a public service for government, media and industry and has been considered a benchmark for national drugs-of-abuse trends since its inception in 1988. Additional company information is available at
'/>"/>

SOURCE Quest Diagnostics
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14

Related medicine news :

1. Quest Diagnostics Board Authorizes $500 Million in Share Repurchases
2. First Study to Test Real-World Effects of Stun Gun Use Raises Questions about Safety
3. Medicsight PLC Receives Additional Information Request for FDA 510(k) Clearance
4. Xmark Sends Letters to Icagens Board of Directors: Questions Companys Leadership as Well as Motives Behind Adoption of Poison Pill
5. Quest Diagnostics to Release Fourth Quarter and Full Year 2008 Financial Results
6. Study of Everest Climbers Questions Oxygen Use
7. Inside out Applesauce Fueling Oklahomas Title Quest
8. U.S. Navy Requested Operations Trial on FDA Hold
9. A simple questionnaire to replace a doctors exam
10. Allsup Outlines 10 Essential Questions People Need to Ask when Evaluating Medicare Plans
11. Hospice Community Encouraged to Respond to Daschle Request to Participate in Information Gathering about Healthcare Concerns
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2014)... Hastings and Hastings, a discount accident lawyer in Phoenix, ... record number of visitors to its new Phoenix personal injury ... cases as well as auto accident cases and slip & ... and others. Having served the state of Arizona for over ... time when it comes to dedicated and focused personal injury ...
(Date:9/19/2014)... (PRWEB) September 19, 2014 Boston Scientific ... mesh lawsuit ( http://www.transvaginalmeshlawsuithelp.com/ ) that is scheduled ... month, Bernstein Liebhard LLP reports. According to ... Court, the company asserts that claims involving its Solyx ... Practice and Remedies Code, a section of which shields ...
(Date:9/19/2014)... (HealthDay News) -- Although there is mounting evidence ... middle-aged and older adults in the United States ... to new research. Less than one-quarter of ... by the Department of Health and Human Services, ... for promoting health and fitness and staying independent, ...
(Date:9/19/2014)... York, NY (PRWEB) September 19, 2014 ... statin medication caused some patients to develop Type 2 ... litigation now underway in U.S. District Court, District of ... Status Report issued on September 12, 2014, discovery is ... things, the report noted that Pfizer, Inc., the manufacturer ...
(Date:9/19/2014)... In partnership with Raw Beauty NYC, OC healthcare agency ... social media efforts. StudioPMG is honored to be a part ... beauty as it applies to disabled women. , The ... and Vanessa Silberman, who wanted to create a photo exhibit ... Wendy Crawford, Susan Solman and Sabrina Cohen later joined in ...
Breaking Medicine News(10 mins):Health News:Hastings And Hastings Announces a Record Number of Visitors to Its New Phoenix Personal Injury Website 2Health News:Transvaginal Mesh Lawsuit Defendant Moves For Summary Judgment in Case Scheduled for Upcoming Texas Trial, Bernstein Liebhard LLP Reports 2Health News:Transvaginal Mesh Lawsuit Defendant Moves For Summary Judgment in Case Scheduled for Upcoming Texas Trial, Bernstein Liebhard LLP Reports 3Health News:Transvaginal Mesh Lawsuit Defendant Moves For Summary Judgment in Case Scheduled for Upcoming Texas Trial, Bernstein Liebhard LLP Reports 4Health News:Adults Over 45 Not Meeting U.S. Muscle Strengthening Guidelines, Study Says 2Health News:Lipitor Lawsuits Move Forward, as Discovery Proceeds in Federal Multidistrict Litigation, Bernstein Liebhard LLP Reports 2Health News:Lipitor Lawsuits Move Forward, as Discovery Proceeds in Federal Multidistrict Litigation, Bernstein Liebhard LLP Reports 3Health News:OC Healthcare Agency StudioPMG Partners with The Raw Beauty Project ™ NYC 2014 2
... Jan. 31 (HealthDay News) -- Super Bowl fans, beware: ... and the Green Bay Packers could be a killer, ... withstand the emotional stress that comes with watching the ... risk appears real, a Los Angeles-based study team cautions, ...
... bacteria to build an extra natural layer of nanoparticle-like armour ... a startlingly simple way to give drug bearing polymer vesicles ... The Warwick researchers have been able to decorate ... new strategy in the design of vehicles for drug release, ...
... is a pathological syndrome that is usually classified into ... the Milwaukee criteria. However, this classification has some drawbacks ... classification and failure to properly guide diagnosis and treatment. ... in the World Journal of Gastroenterology addresses ...
... Oncology (ISCO) will collaborate to publish Cellular Oncology ... the official journal of ISCO and publishes original papers ... It was previously published by IOS Press. ... clinical disciplines involved in basic and translational cancer research ...
... , SATURDAY, Jan. 29 (HealthDay News) -- An ... decided on Friday that electroconvulsive (also known as "electroshock") ... as other medical devices entering the market. ... decades-old controversy surrounding the psychiatric treatment, which some patients ...
... Jan. 30 (HealthDay News) -- It may not be news to those ... reports that if you,re aboard a ship, looking at the horizon can ... investigators compared a group of crew members as they stood on land ... front of them and then a far-off object -- a distant mountain ...
Cached Medicine News:Health News:Super Bowl Loss Really a Heart Stopper for Some Fans 2Health News:Super Bowl Loss Really a Heart Stopper for Some Fans 3Health News:Plankton inspires creation of stealth armor for slow-release microscopic drug vehicles 2Health News:Springer to publish Cellular Oncology 2Health News:FDA Panel Recommends Testing of Electroshock Devices 2Health News:FDA Panel Recommends Testing of Electroshock Devices 3Health News:FDA Panel Recommends Testing of Electroshock Devices 4
(Date:9/19/2014)... R.I. , Sept. 19, 2014 Larry ... CVS ), will speak before the National Press ... will discuss the company,s recent move to stop selling tobacco ... shape the future of health. "Dramatic changes in ... health care providers and government," Merlo has said. "CVS Health ...
(Date:9/19/2014)... -- Alere Inc. (NYSE: ALR ), a global ... in support of President Barack Obama,s Executive ... leader in rapid diagnostics for infectious disease, we commend ... the serious threat of antibiotic resistance. We look forward ... to promote the development of rapid point-of-care tests that, ...
(Date:9/19/2014)... 19, 2014  Lpath, Inc. (NASDAQ: ... therapeutics, announced today that it has entered into ... common stock and 3,605,042 unregistered warrants in a ... one registered share of common stock and one ... common stock will be $3.475.  The warrants have ...
Breaking Medicine Technology:CVS Health CEO to Address National Press Club on Landmark Decision to Quit Tobacco, Leadership in Health Care Innovation 2CVS Health CEO to Address National Press Club on Landmark Decision to Quit Tobacco, Leadership in Health Care Innovation 3Alere Applauds President's Executive Order Combating Antibiotic-Resistant Bacteria 2Lpath, Inc. Announces $12.5 Million Registered Direct Offering 2Lpath, Inc. Announces $12.5 Million Registered Direct Offering 3
... Surgeons at Self Regional Healthcare,s South Carolina Spine Center ... variety of spinal conditions in its new advanced surgical ... Already recognized by leading health care ratings organization ... continues its commitment to advanced spinal care by becoming ...
... announced today the company has reached another major milestone ... management team roster. DiFUSION Technologies is ... commercialization of its proprietary CleanFUZE ™ anti-microbial technology ... line of Posterior Interbody products. "In ...
Cached Medicine Technology:Self Regional Healthcare Becomes First in the Southeast to Treat Spine Patients Using Advanced Integrated Operating Room Technology From Brainlab 2DiFUSION Technologies Adds Accomplished Senior Management Team 2DiFUSION Technologies Adds Accomplished Senior Management Team 3DiFUSION Technologies Adds Accomplished Senior Management Team 4DiFUSION Technologies Adds Accomplished Senior Management Team 5
BD Vacutainer® Heparin Tubes are spray-coated with either lithium heparin or sodium heparin and are used for plasma determinations in chemistry....
VACUETTE paediatric tubes have decreased sample volumes and are ideal for small childrens' veins and geriatric patients....
... Coagulation tubes contain a buffered ... available with a citrate concentration ... 0.129 mol/l (3.8%). The mixing ... solution to 9 parts blood. ...
... are available in two versions. ... a clotting activator and is ... serum is required for testing ... is suitable where the testing ...
Medicine Products: